1. Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Issue 9 (September 2021) Authors: Hoppe, Jordana E; Chilvers, Mark; Ratjen, Felix; McNamara, John J; Owen, Caroline A; Tian, Simon; Zahigian, Rachel; Cornell, Alexandra G; McColley, Susanna A Journal: Lancet Issue: Volume 9:Issue 9(2021) Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗